The Latest in Lung Cancer

ALK inhibitor alectinib shows DFS benefit in early NSCLC

October 22, 2023

Lung Cancer

Perioperative nivolumab improves EFS in resectable NSCLC

October 22, 2023

Neoadjuvant advantages: Treating locally advanced lung cancer

October 18, 2023

Lung Cancer

This is how you get patients back for follow-up cancer testing

October 10, 2023

Higher RT doses can boost lifespan, reduce risk of death in LS-SCLC patients

October 5, 2023

Reducing cognitive impairment from SCLC brain metastases

October 4, 2023

These adverse events linked to improved cancer prognosis

September 28, 2023

Therapeutic vaccine shows promise in treating lung cancer

September 20, 2023

Lung Cancer

New ‘C word’: Cure should be the goal for patients with lung cancer

September 20, 2023

Lung Cancer

Many patients with NSCLC receive immunotherapy ‘indefinitely’ – Are they benefiting?

September 18, 2023

Lung Cancer

Nivolumab/Ipillimumab combo demonstrates long-term efficacy in NSCLC

September 18, 2023

Proposed TNM update could shift staging for lung cancers

September 14, 2023

Lung Cancer

Neoadjuvant durvalumab does not affect surgical outcomes in NSCLC: Study

September 14, 2023

Lung Cancer

Osimertinib plus chemo ups PFS, toxicity in first line

September 14, 2023

Surgery may worsen pleural mesothelioma survival outcomes

September 13, 2023